Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRDX Stock Forecast 2026-2027
$42.98
Current Price
$614.58M
Market Cap
Buy 0
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to SRDX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
SRDX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+50.5%
1 Year Change
0.0%
Year-to-Date Change
-0.1%
From 52W High of $43.00
+66.1%
From 52W Low of $25.87
📊 TOP ANALYST CALLS
Did SRDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Surmodics is one of their latest high-conviction picks.
Latest SRDX Stock Price Targets & Analyst Predictions
SRDX has shown a year-to-date change of 0.0% and a 1-year change of 50.5%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for SRDX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRDX Analyst Ratings
0
Buy
1
Hold
1
Sell
SRDX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $42.98
Latest SRDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | Barrington Research | Michael Petusky | Underperform | Downgrade | $N/A |
| Aug 11, 2025 | Barrington Research | Michael Petusky | Market Perform | Reiterates | $N/A |
| Apr 30, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Mar 7, 2025 | Lake Street | Brooks O'Neil | Buy | Upgrade | $43.00 |
| Jan 30, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Nov 7, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Aug 5, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| May 30, 2024 | Barrington Research | Michael Petusky | Market Perform | Downgrade | $N/A |
| May 29, 2024 | Lake Street | Brooks O'Neil | Hold | Downgrade | $43.00 |
| May 29, 2024 | Needham | Mike Matson | Hold | Downgrade | $N/A |
| May 29, 2024 | Sidoti & Co. | James Sidoti | Neutral | Downgrade | $43.00 |
| May 2, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $71.00 |
| May 1, 2024 | Needham | Mike Matson | Buy | Maintains | $43.00 |
| Apr 10, 2024 | Needham | Mike Matson | Buy | Reiterates | $47.00 |
| Feb 1, 2024 | Needham | Mike Matson | Buy | Maintains | $47.00 |
| Nov 9, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $71.00 |
| Nov 8, 2023 | Needham | Mike Matson | Buy | Maintains | $44.00 |
| Aug 2, 2023 | Needham | Mike Matson | Buy | Reiterates | $50.00 |
| Jun 21, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $69.00 |
| Jun 20, 2023 | Needham | Mike Matson | Buy | Reiterates | $36.00 |
Surmodics Inc. (SRDX) Competitors
The following stocks are similar to Surmodics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SRDX
Surmodics
mkt cap
614.58M
Surmodics Inc. (SRDX) Financial Data
Surmodics Inc. has a market capitalization of $614.58M with a P/E ratio of 43.0x. The company generates $120.80M in trailing twelve-month revenue with a -14.6% profit margin.
Revenue growth is -2.6% quarter-over-quarter, while maintaining an operating margin of +0.2% and return on equity of -15.4%.
Valuation Metrics
Market Cap
$614.58M
Enterprise Value
$614.37M
P/E Ratio
43.0x
PEG Ratio
-1.4x
Price/Sales
5.1x
Growth & Margins
Revenue Growth (YoY)
-2.6%
Gross Margin
+45.4%
Operating Margin
+0.2%
Net Margin
-14.6%
EPS Growth
-2.6%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
3.9x
Debt/Equity
29.3x
ROE
-15.4%
ROA
-0.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Surmodics Inc. (SRDX) Business Model
About Surmodics Inc.
What They Do
Develops drug delivery and surface modification technologies.
Business Model
Surmodics generates revenue by partnering with medical device and pharmaceutical companies to provide specialized coating and drug delivery solutions. Their expertise enhances the performance and safety of medical devices, allowing them to charge for their innovative technologies and services.
Additional Information
Founded in 1979 and based in Eden Prairie, Minnesota, Surmodics Inc. is a key player in the healthcare sector, focusing on improving therapeutic outcomes through advanced medical technology. The company is involved in various applications, particularly in vascular and endovascular sectors, and collaborates with industry leaders to drive innovation in medical solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
389
CEO
Mr. Gary R. Maharaj
Country
United States
IPO Year
1998
Website
www.surmodics.comSurmodics Inc. (SRDX) Latest News & Analysis
Latest News
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
5 months ago
Quick Summary
Surmodics, Inc. (Nasdaq: SRDX) announced it expects to close its acquisition by GTCR LLC soon, as detailed in a joint court status report.
Why It Matters
Surmodics' merger with GTCR signals potential growth and strategic realignment, affecting its market position and future profitability, which can impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The U.S. District Court in Illinois denied the FTC's request for a preliminary injunction against GTCR's acquisition of Surmodics Inc. (NASDAQ:SRDX).
Why It Matters
The court's denial of the injunction allows GTCR's acquisition of Surmodics to proceed, potentially enhancing Surmodics' market position and impacting stock performance positively.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Surmodics, Inc. announced that a U.S. District Court denied the FTC's request for a preliminary injunction against the company and GTCR, allowing business operations to continue.
Why It Matters
The court's decision allows Surmodics to proceed with its business plans without regulatory delays, potentially boosting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Surmodics, Inc. (Nasdaq: SRDX) announced that Dr. Sean Lyden and colleagues will present updated safety and performance data from the PROWL registry on the Pounce™ Thrombectomy Platform on Monday.
Why It Matters
The presentation of updated safety and performance data for Surmodics' Pounce™ Thrombectomy Platform could influence investor confidence and stock performance, reflecting potential market expansion and product viability.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Surmodics, Inc. (Nasdaq: SRDX) presented findings from its PROWL registry study on 160 patients with infrainguinal limb ischemia at the VIVA Conference in Las Vegas on November 3rd.
Why It Matters
Surmodics' presentation of PROWL study results may boost its credibility and attract investor interest, potentially impacting stock performance in the medical device sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Surmodics reported a narrower loss in Q3 fiscal 2025, with revenue exceeding estimates, despite a decline in SurVeil DCB sales.
Why It Matters
Surmodics' earnings beat and revenue exceeding estimates signal operational resilience, potentially boosting investor confidence despite challenges in specific product sales.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About SRDX Stock
What is Surmodics Inc.'s (SRDX) stock forecast for 2026?
Analyst forecasts for Surmodics Inc. (SRDX) are not currently available. The stock is trading at $42.98.
Is SRDX stock a good investment in 2026?
According to current analyst ratings, SRDX has 0 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $42.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRDX stock?
Price predictions from Wall Street analysts for SRDX are not currently available. The stock is trading at $42.98.
What is Surmodics Inc.'s business model?
Surmodics generates revenue by partnering with medical device and pharmaceutical companies to provide specialized coating and drug delivery solutions. Their expertise enhances the performance and safety of medical devices, allowing them to charge for their innovative technologies and services.
What is the highest forecasted price for SRDX Surmodics Inc.?
Price targets from Wall Street analysts for SRDX are not currently available. The stock is trading at $42.98.
What is the lowest forecasted price for SRDX Surmodics Inc.?
Price targets from Wall Street analysts for SRDX are not currently available. The stock is trading at $42.98.
What is the overall SRDX consensus from analysts for Surmodics Inc.?
The overall analyst consensus for SRDX is neutral. Out of 5 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 1 as Sell.
How accurate are SRDX stock price projections?
Stock price projections, including those for Surmodics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 8:30 PM UTC